{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:18:47Z","timestamp":1767665927472},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.02.068","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T13:06:44Z","timestamp":1709557604000},"page":"2347-2356","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice"],"prefix":"10.1016","volume":"42","author":[{"given":"Ashley C.","family":"Beavis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Dienger-Stambaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.02.068_b0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.02.068_b0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.6601823","article-title":"Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Gallo","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.02.068_b0015","first-page":"319","article-title":"Lymphadenopathy associated virus and its etiological role in AIDS","volume":"15","author":"Montagnier","year":"1984","journal-title":"Princess Takamatsu Symp"},{"key":"10.1016\/j.vaccine.2024.02.068_b0020","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/35073639","article-title":"The global impact of HIV\/AIDS","volume":"410","author":"Piot","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.02.068_b0025","article-title":"Major scientific hurdles in HIV vaccine development: historical perspective and future directions","volume":"11","author":"Ng'uni","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0030","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/319863","article-title":"Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers","volume":"183","author":"Belshe","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0035","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.02.068_b0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-114-2-119","article-title":"The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS vaccine clinical trials network","volume":"114","author":"Dolin","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.02.068_b0045","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clinthera.2020.01.009","article-title":"Innovations in HIV-1 vaccine design","volume":"42","author":"Jones","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2024.02.068_b0060","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0065","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20081524","article-title":"Macaques vaccinated with live-attenuated SIV control replication of heterologous virus","volume":"205","author":"Reynolds","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2024.02.068_b0070","doi-asserted-by":"crossref","first-page":"e0202753","DOI":"10.1371\/journal.pone.0202753","article-title":"Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial","volume":"13","author":"Elizaga","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.02.068_b0075","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/infdis\/173.2.330","article-title":"A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS vaccine evaluation group","volume":"173","author":"Gorse","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.vaccine.2008.10.051","article-title":"Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial","volume":"27","author":"Spearman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.068_b0085","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jiq175","article-title":"A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers","volume":"203","author":"Spearman","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0090","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/560347","article-title":"HIV vaccine: recent advances, current roadblocks, and future directions","volume":"2015","author":"Rubens","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2024.02.068_b0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12977-018-0457-7","article-title":"HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth","volume":"15","author":"van Schooten","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.vaccine.2024.02.068_b0100","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.02.068_b0105","doi-asserted-by":"crossref","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.02.068_b0110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"Montefiori","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.068_b0115","article-title":"Another HIV vaccine strategy fails in large-scale study","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.02.068_b0120","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/icb.1977.63","article-title":"A new mouse paramyxovirus (J virus)","volume":"55","author":"Jun","year":"1977","journal-title":"Aust J Exp Biol Med Sci"},{"key":"10.1016\/j.vaccine.2024.02.068_b0125","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.02.068_b0130","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1073\/pnas.1509476112","article-title":"Type II integral membrane protein, TM of J paramyxovirus promotes cell-to-cell fusion","volume":"112","author":"Li","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2024.02.068_b0135","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1128\/JVI.79.16.10690-10700.2005","article-title":"The complete genome sequence of J virus reveals a unique genome structure in the family Paramyxoviridae","volume":"79","author":"Jack","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00066-17","article-title":"A single-dose recombinant Parainfluenza virus 5-vectored vaccine expressing respiratory syncytial virus (RSV) F or G protein protected cotton rats and African green monkeys from RSV challenge","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2024.02.068_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.623996","article-title":"Parainfluenza virus 5 priming followed by SIV\/HIV virus-like-particle boosting induces potent and durable immune responses in nonhuman primates","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00653-18","article-title":"Role of small hydrophobic protein of J Paramyxovirus in virulence","volume":"92","author":"Abraham","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/JVI.02321-12","article-title":"Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0170","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/JVI.02886-12","article-title":"A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein","volume":"87","author":"Chen","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0175","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1016\/j.vaccine.2015.10.124","article-title":"Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.068_b0180","doi-asserted-by":"crossref","unstructured":"Lafontaine ER, Chen Z, Huertas-Diaz MC, Dyke JS, Jelesijevic TP, Michel F, Hogan RJ, He B. The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei. Vaccine X. 2018 Dec 22;1:100002. doi: 10.1016\/j.jvacx.2018.100002. eCollection 2019 Apr 11.","DOI":"10.1016\/j.jvacx.2018.100002"},{"key":"10.1016\/j.vaccine.2024.02.068_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00554-20","article-title":"Single-dose, intranasal immunization with recombinant Parainfluenza virus 5 expressing middle east respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection","volume":"11","author":"Li","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2024.02.068_b0200","doi-asserted-by":"crossref","first-page":"e50144","DOI":"10.1371\/journal.pone.0050144","article-title":"Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.02.068_b0205","doi-asserted-by":"crossref","first-page":"8842","DOI":"10.1128\/JVI.01163-16","article-title":"Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA\/modified Vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques","volume":"90","author":"Iyer","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.02.068_b0210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.virol.2006.12.005","article-title":"Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge","volume":"362","author":"Tompkins","year":"2007","journal-title":"Virology"},{"issue":"23","key":"10.1016\/j.vaccine.2024.02.068_b0220","doi-asserted-by":"crossref","first-page":"14804","DOI":"10.1128\/JVI.79.23.14804-14814.2005","article-title":"Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization","volume":"79","author":"Hammonds","year":"2005","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:30:23Z","timestamp":1723059023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24002275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24002275"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}